Tandem Diabetes Care, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Tandem Diabetes Care, Inc. (TNDM) reported Net Income (Loss) Available to Common Stockholders, Diluted of $755.00 thousand for the 3-month period ending 2024-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-02-19
- Tandem Diabetes Care, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-12-31 was $755.00K.
- Tandem Diabetes Care, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2022-12-31 was -$15.85M, a 246.25% decline year-over-year.
- Tandem Diabetes Care, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-12-31 was $10.84M, a 23.56% decline year-over-year.
- Tandem Diabetes Care, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was $5.79M.
- Tandem Diabetes Care, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$222.61M.
- Tandem Diabetes Care, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$94.59M, a 707.70% decline from fiscal 2021.
- Tandem Diabetes Care, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was $15.57M.
- Tandem Diabetes Care, Inc. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$34.38M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $755.00K 10-K · filed 2026-02-19 | $754.00K 10-K · filed 2025-02-26 | |||
| 2023-12-31 | -$222.61M 10-K · filed 2024-02-21 | ||||
| 2022-12-31 | -$15.85M 10-K · filed 2023-02-22 | -$94.59M 10-K · filed 2024-02-21 | |||
| 2021-12-31 | $10.84M 10-K · filed 2023-02-22 | $16.63M derived: sum of 2 quarters · filed 2023-02-22 | $20.64M derived: sum of 3 quarters · filed 2023-02-22 | $15.57M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $5.79M 10-Q · filed 2022-11-02 | $9.80M derived: sum of 2 quarters · filed 2022-11-02 | $4.76M 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | $4.01M 10-Q · filed 2022-08-03 | ||||
| 2020-12-31 | $14.18M 10-K · filed 2022-02-22 | -$34.38M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $2.65M 10-K · filed 2021-02-24 | -$2.57M derived: sum of 2 quarters · filed 2021-02-24 | |||
| 2019-09-30 | -$5.22M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |